In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Medivation licenses exclusive rights to CureTech's Phase II cancer project pidilizumab

Executive Summary

CureTech Ltd. granted Medivation Inc. exclusive global rights to develop and sell pidilizumab (CT011) in all indications, including cancer. The anti-PD-1 antibody is in Phase II studies for blood and solid tumors.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register